Recruiting
Phase 2

Minimizing Toxicity in HLA-identical Related Donor Transplantation for Children With Sickle Cell Disease

Sponsor:

Robert Nickel

Code:

NCT03587272

Conditions

Sickle Cell Disease

Eligibility Criteria

Sex: All

Age: 2 - 25

Healthy Volunteers: Not accepted

Interventions

Alemtuzumab, low dose total body irradiation, Sirolimus

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information